洛匹那韦/利托那韦治疗新型冠状病毒肺炎致腹泻及防治的回顾性分析

洛匹那韦/利托那韦治疗新型冠状病毒肺炎致腹泻及防治的回顾性分析2020年第32卷第四期)

杨思芸1,2  梁婧1,2  刘涛2,3  李红英4  张仕瑾1,2  随何欢1,2  梁建英5

1.南充市中心医院药学部,四川 南充 637000;2.个体化药物治疗南充市重点实验室,四川 南充 637000;3.南充市中心医院心血管内科,四川 南充 637000;4.蓬安县人民医院药剂科,四川 南充 637000;5.南充市中心医院感染科,四川 南充 637000)

【摘要】  目的 探讨南充地区新型冠状病毒肺炎(COVID-19)患者使用洛匹那韦/利托那韦导致腹泻的特点及规律,为临床安全用药及防治提供参考依据。方法 对南充市9家定点收治新型冠状病毒肺炎的医疗机构使用洛匹那韦/利托那韦治疗的患者资料进行回顾性分析,包括患者主要不良反应类型、严重程度、不同处理方法及预后的因素。结果 截至2020年2月17日,南充市定点收治新型冠状病毒肺炎病例共35例,其中33例给予洛匹那韦/利托那韦(200mg/50mg)2粒 BID抗病毒治疗,其余均对症支持治疗。药物使用过程中,发生腹泻15例,其中单纯腹泻11例、腹泻伴呕吐感3例、腹泻伴皮疹1例,腹泻不良反应的发生率达45.45%,经过治疗,14例治愈,1例续观。结论 对症支持疗法是治疗新型冠状病毒肺炎的关键。当新型冠状病毒肺炎患者使用洛匹那韦/利托那韦出现恶心呕吐、腹泻等不良反应时,建议采取停药或对症处理等措施。

  【关键词】  新型冠状病毒肺炎;19冠状病毒疾病;洛匹那韦/利托那韦;药品不良反应;

  【中图分类号】R511;R183   【文献标志码】A 

 

Retrospective analysis of diarrhea associated with lopinavir-ritonavir for COVID-19 and its prevention

YANG Siyun1,2,LIANG Jing1,2, LIU Tao2,3,LI Hongying4,ZHANG Shijin1,2,SUI Hehuan1,2, LIANG Jianying5

1.Department of Pharmacy, Central Hospital of Nanchong, Nanchong 637000, Sichuan, China;2. Nanchong Key Laboratory of Individualized Drug Therapy, Nanchong 637000 , Sichuan, China;3. Department of Cardiovascular Medicin, Central Hospital of Nanchong, Nanchong 637000, Sichuan, China;4. Department of Pharmacy, Peng’an County People's Hospital, Nanchong 637000, Sichuan, China;5. Department of Infectious Diseases, Central Hospital of Nanchong, Nanchong 637000, Sichuan, China)

Abstract】  Objective  To understand the characteristics and rules of adverse reactions of corona virus disease-19(COVID-19) in Nanchong area using lopinavirritonavir, so as to provide evidence for clinical medication safety and effectiveness. Methods  COVID-19 cases in 9 hospitals in Nanchong were collected and investigated by retrospective analysis. The main adverse reaction types, different treatment methods, treatment measures and prognosis were collected and analyzed. Results  As of February 17, 2020, 35 cases of COVID-19 in Nanchong were admitted, among these 33 cases were treated with the diagnostic protocol of COVID19. Patients were given lopinavirritonavir 200mg/50mg BID for antiviral therapy, at the same time, other symptoms were treated with symptomatic support. In the course of drug use, 18 patients had different degrees of diarrhea, rash and other adverse drug reactions. There were 11 cases of diarrhea, 3 cases of diarrhea with vomiting, 1 case of diarrhea with rash. The incidence of diarrhea adverse reactions was as high as 45.45%.Conclusion  COVID-19 in the region has been explored and summarized for nearly a month, and symptomatic supportive therapy is the key of treating COVID-19. When COVID-19 patients who have used lopinavir-ritonavir appeared adverse reactions such as nausea, vomiting and diarrhea, it is recommended to take measures such as stopping or symptomatic treatment.

Key words】  COVID-19; Lopinavir-Ritonavir; Adverse drug reactions; Diarrhea

 

全文:洛匹那韦利托那韦治疗新型冠状病毒肺炎致腹泻及防治的回顾性分析

用微信扫一扫

用微信扫一扫